28 results about "Dissociation constant" patented technology

The invention provides a nucleic acid aptamer for specific recognition of morphine and application of the nucleic acid aptamer, and belongs to the technical field of biosensing and detection. The nucleotide sequence of the nucleic acid aptamer is as shown in SEQ ID NO: 1. The screening method is based on a Capture-SELEX technology and comprises the key steps that streptavidin magnetic beads are used for fixing an ssDNA library, estradiol, deabietic acid and totarol are introduced to serve as reverse screening substances so as to remove non-specific sequences, and finally the high-specificity aptamer is obtained through high-throughput sequencing and affinity determination. The dissociation constant of the aptamer and morphine is 127.31 nM, and the aptamer shows high affinity and high specificity. The invention further relates to application of the aptamer in preparation of a sensor and a kit for detecting morphine, and a new technical means is provided for rapid detection of morphine.

HPV16 is a main cause of malignant tumors such as cervical cancer, and E6 protein of HPV16 becomes a key treatment and diagnosis target. In the prior art, an HPV16 detection antibody has the problems of poor stability, dependence on cold chain transportation, low preparation efficiency and the like. According to the invention, a nano antibody sequence which is high in affinity (dissociation constant KD is less than or equal to 1 * 10 <-7 > M) and stable at room temperature is obtained through total synthesis library construction and a phage-assisted directed evolution (PACE) screening technology. After the antibody is stored at 25 DEG C for 30 days, the activity of the antibody is kept to be greater than or equal to 95%, the antibody can be directly used for household test paper, the accuracy rate reaches 98%, and meanwhile, the antibody can be expanded to medical applications such as CAR-T cell therapy. Compared with a traditional antibody, the antibody has the advantages of being short in preparation period, low in cost, wide in application scene and the like, and a breakthrough solution is provided for early screening of cervical cancer.

The invention discloses a screening method and application of a shark-derived anti-idiotypic nano antibody, and belongs to the technical field of biological pharmacy and vaccines. The screening method comprises the following steps: immunizing adult shark by using a target pathogen specific antigen, collecting peripheral blood, separating lymphocytes, extracting RNA (Ribonucleic Acid), carrying out reverse transcription to synthesize cDNA (Complementary Deoxyribonucleic Acid), amplifying a nano antibody variable region fragment of a shark IgNAR (Immunoglobulin Nucleic Acid Receptor) gene, and constructing a phage display gene bank of which the storage capacity is greater than or equal to 1 * 10 < 8 > CFU and the recombination rate is greater than or equal to 85%; a variable region of a target pathogen specific antibody is taken as a target, specific bacteriophage is enriched through 3-4 rounds of gradient washing and elutriation (Tween-20 concentration and washing time are gradually improved), and the shark source anti-idiotypic nano antibody with high affinity and high purity (greater than or equal to 95%) is obtained by combining ELISA screening positive clone, gene sequencing de-weighting and SPR detection (combining dissociation constant KDlt, 1 * 10 <-7 > mol / L).

The present application relates to an assay method using affinity crosslinking of DNA-linked ligands to proteins to enable small molecule screening and determination of apparent affinity constants of ligands to the proteins. This method has been applied to determine 96 compounds' dissociation constants to a protein target simultaneously, and directly determine a compound's IC50 against five protein targets concurrently in crude cell lysates. Additionally, this approach was used to screen a Library of Pharmacologically Active Compounds (LOPAC) library against dihydrofolate reductase (eDHFR), enabling the discovery of a novel eDHFR inhibitor (IC50=7.9 μM). An assay kit and the method of uses are within the scope of this disclosure.

The application discloses a nucleic acid aptamer of maytansine and application thereof, the nucleic acid aptamer is Seq2-X, and a DNA sequence of Seq2-X is shown as SEQ ID NO. 1. The nucleic acid aptamer can be combined with the target maytansine with high affinity and high specificity, the equilibrium dissociation constant is in the nanomolar range, the water solubility is good, and after being combined with the fat-soluble maytansine, the solubility of the drug can be improved. By utilizing the specific interaction between the nucleic acid aptamer and maytansine, the stability of maytansine drug can be improved, the cytotoxicity of maytansine is enhanced, and the treatment window is widened. By utilizing the nucleic acid aptamer as a drug delivery carrier of maytansine, the limitation of maytansine in clinical application can be improved, which has important significance for the design and development of maytansine drugs in clinical application.

The embodiment of the invention discloses a method for screening a tumor immune checkpoint inhibitor based on electrochemical luminescence sensing. According to the invention, an electrochemiluminescence sensor is established, and resonance energy transfer between luminol (an electrochemiluminescence donor) and a PD-L1-targeting metal cluster (an electrochemiluminescence receptor) is utilized; the electrochemical luminescence sensor capable of rapidly, sensitively, simply, conveniently and quantitatively analyzing the equilibrium dissociation constant between the non-antibody immune checkpoint inhibitor and the PD-L1 expressed on the tumor cell membrane at low cost is established. The efficiency of blocking the PD-1 / PD-L1 by the inhibitor is evaluated through quantitative analysis of the constant, so that the potential non-antibody immune checkpoint inhibitor is effectively screened.

The invention discloses a nucleic acid aptamer targeting aflatoxin B1 as well as an acquisition method and application of the nucleic acid aptamer. The relative molecular weight of the aflatoxin B1 is only 312.27, and the molecular structure is lack of active groups for directional coupling under mild conditions, so that the aflatoxin B1 is difficult to fix on the surface of a solid-phase carrier on the premise of not damaging the main conformation or key recognition sites of the aflatoxin B1. According to the invention, an optimized Capture-SELEX screening method is adopted, so that not only is the nucleic acid aptamer targeting aflatoxin B1 successfully screened, but also the dissociation constant (Kd value) of the nucleic acid aptamer measured by an isothermal titration calorimetry is extremely low, which indicates that the target affinity of the nucleic acid aptamer is extremely strong.

The invention discloses a sequence-based protein-ligand binding and affinity prediction method, which comprises the following steps of: 1, acquiring a prediction data set, and carrying out data processing on the prediction data set; the prediction data set comprises an amino acid sequence of a protein, an SMILE sequence of a ligand, whether the protein and the ligand can be combined with a tag or not, and a protein and ligand binding affinity dissociation constant; step 2, constructing a protein-ligand binding and affinity prediction model; step 3, training the protein-ligand binding and affinity prediction model by using the data set after data processing; and step 4, inputting the amino acid sequence of the protein and the SMILE sequence of the corresponding ligand into the trained protein-ligand binding and affinity prediction model to obtain a prediction result of whether the protein and the ligand can be bound or not and the binding affinity. According to the method, the accuracy and generalization ability of the prediction model and the interpretability of the model are improved.

The application discloses a digoxin nanobody and a preparation method and application thereof. The amino acid and nucleotide sequences of the digoxin nanobody are shown in SEQ ID NO. 8-9. The antibody has good affinity to a target antigen, and the dissociation constant Kd value is about 73.1 nM, and can be used for digoxin content determination, nucleic acid probe detection and in-vivo digoxin neutralization and detoxification. The antibody has the advantages of small volume, high stability, low cost, low immunogenicity and the like, and has a good application prospect.

The invention discloses a VHH chain of an anti-TrxA nano antibody and application of the VHH chain, and belongs to the technical field of nano antibodies. The VHH chain of the anti-TrxA nano antibody disclosed by the invention comprises amino acid sequences of FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4; according to the anti-TrxA nano antibody obtained by the invention, the dissociation constant (KD) of the nano antibody and a TrxA antigen reaches 2.29 * 10 <-9 > M, and the nano antibody shows excellent binding dynamic characteristics and high affinity. The kit can be used for ELISA and WB detection of TrxA recombinant protein.

The purpose of the present invention is to provide a method for efficiently producing an oligonucleotide by a solid-phase synthesis approach. The present invention provides a method for producing an oligonucleotide by a solid phase synthesis approach, the method comprising a step for reacting an oligonucleotide in which a hydroxyl group at a chain extendable end is protected with a protective group that can be removed under acidic conditions and a deblocking solution to remove a protective group for a hydroxyl group at the chain extendable end, wherein the deblocking solution is a deblocking solution containing a base, an acid, and an aprotic solvent, and the base is a base having an acid dissociation constant (pKa) of a conjugate acid of 5-12, and an oligonucleotide in which the content ratio of the 2', 3'transfer body is a certain amount or less.

The invention relates to the technical field of biological medicines, and provides an aptamer specifically bound with lipophilic polyether toxin as well as a screening method and application of the aptamer. An RNA-Capture SELEX technology optimization scheme is adopted to obtain an RNA aptamer R1852, the RNA aptamer R1852 can be simultaneously combined with OA, DTX-1 and AZA-1 toxins with high affinity, and equilibrium dissociation constants (Kd) are as follows: OA: 2.139 * 10 <-6 > M; dTX-1: 3.755 * 10 <-7 > M; and AZA-1: 2.429 * 10 <-6 > M. The invention also discloses the aptamer. As a molecular recognition probe capable of being specifically combined with OA, DTX-1 and AZA-1 at the same time, the aptamer has the advantages of being high in affinity, high in specificity, good in stability, low in immunogenicity, easy to synthesize, modify and mark and the like. The method can be used for separation, enrichment and detection of trace OA, DTX-1 and AZA-1 in water or aquatic product samples, and rapid detection and removal of OA, DTX-1 and AZA-1 toxins in water or aquatic products are realized.

To provide an improved analysis method or the like capable of analysis using a specific bonding function of DNA.SOLUTION: The analysis method is an analysis method for analyzing a target substance in a sample using the sample that may contain the target substance, the analysis method including: Acquiring a first signal of the sample after the reaction, reacting the sample with a second test substance containing a DNA assembly consisting of DNA of one or more types of sequences and acquiring a second signal of the sample after the reaction, and analyzing the target substance in the sample based on a difference between the first signal and the second signal, wherein a dissociation constant between the DNA assembly and the target substance is larger than a dissociation constant between the aptamer and the target substance.SELECTED DRAWING: Figure 6

The application provides a structure-based evaluation model for equilibrium dissociation constant of a peptide ligand molecule and a target protein, comprising: obtaining of peptide ligand equilibrium dissociation constant data; obtaining of peptide ligand and receptor protein interaction relationship characteristic data; data set for algorithm system construction: construction of a targeting IgG series polypeptide characteristic library and a targeting alpha beta 42 series polypeptide characteristic library, and construction of an independent verification data set; using the targeting IgG series polypeptide characteristic library to construct a machine learning algorithm classifier system, optimizing related parameters, testing by using the targeting alpha beta 42 series polypeptide characteristic library, and evaluating system performance; and evaluating actual prediction performance of the system by using the constructed related independent data set. The application uses a virtual screening method to study a peptide ligand and a target protein interaction region, which can further improve drug screening efficiency and reduce corresponding cost.

This specification provides antigen-binding protein constructs (ABPCs) that bind to TROP2 and their use. This specification provides antigen-binding protein constructs (ABPCs) and pharmaceutical compositions comprising an effective amount of ABPC, comprising a first antigen-binding domain (ABD) that can specifically bind to TROP2 or an epitope of TROP2 presented on the surface of a target mammalian cell, wherein (a) the dissociation rate of the first ABD at pH about 4.0 to about 6.5 is faster than the dissociation rate at pH about 7.0 to about 8.0, and / or (b) the dissociation constant (KD) of the first ABD at pH about 4.0 to about 6.5 is greater than the KD at pH about 7.0 to about 8.0.

This application relates to the field of tumor immunodiagnostic technology, and particularly to a monoclonal antibody, polynucleotide, preparation method, and application of antiphosphatidylinositol proteoglycan-3; the monoclonal antibody includes a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region includes heavy chain region CDR1 with amino acid sequence as shown in SEQ ID NO:1, heavy chain region CDR2 with amino acid sequence as shown in SEQ ID NO:2, and heavy chain region CDR3 with amino acid sequence as shown in SEQ ID NO:3; the light chain variable region includes light chain region CDR1 with amino acid sequence as shown in SEQ ID NO:4, light chain region CDR2 with amino acid sequence as shown in SEQ ID NO:5, and light chain region CDR3 with amino acid sequence as shown in SEQ ID NO:6; the dissociation constant KD(M) of the monoclonal antibody against GPC3 antigen is 1.21E-11, which is a high-affinity N-terminal antibody, suitable for the detection of GPC3 in clinical serum samples.

The present invention relates to novel albumin binding constructs that enhance the pharmacokinetic performance of therapeutic peptides and proteins, extend their half-life and reduce the frequency of administration. The core peptide DICLPRWGCLW (SEQ ID NO: 1) is covalently linked to a hydrophilic and flexible glycine-serine (Gly-Ser) linker of the formula (ggs) xg, wherein x is from 3 to 8 units. The linkers provide a strong binding force (dissociation constant lt; 20 nanomoles) to albumin. Some constructs have a GGSGGSGGSGGRLIEDICLPRGCLWEDD (SEQ ID NO: 4) peptide, allowing fusion of active proteins, such as Klotho, maintaining biological activity, and utilizing the long half-life of albumin. In some embodiments, constructs are produced using cellular expression systems (CHO cells, HEK293 cells, transgenic insect cells) to ensure scalability. Upon administration, these constructs exhibit an extended half-life up to at least 90% of the half-life of native albumin. The novel Klotho constructs using the novel albumin conjugates show a FGF23 binding dissociation constant of from 15 to 30 nanomoles, substantially the same as that of natural Klotho. These constructs are designed to minimize antigenicity, thereby enhancing drug delivery effectiveness and improving patient prognosis.

The invention relates to the technical field of component design, in particular to a benzene ring acid group substitution type screening method based on isoamyl cinnamate and application of the benzene ring acid group substitution type screening method based on isoamyl cinnamate. The screening method comprises the steps that a virtual substituent library is established, acid group substituents are introduced to an isoamyl cinnamate benzene ring, and a plurality of substitution combinations are generated; predicting a minimum value pKai of an acid dissociation constant and a polar atom ratio PAR for each structure, and screening less than or equal to 50 candidate structures according to the minimum value pKai and the polar atom ratio PAR; measuring the fluorescence polarization anisotropy r of each candidate structure, and screening the first 50% of samples according to the sequence of r values from small to large; sequentially measuring the quantum dot fluorescence intensity retention rate Fret and the coating UVB retention rate RAUVB of the screened samples; and outputting the acid group substitution type corresponding to the maximum value according to the product sequence of the two. The self anti-ultraviolet attenuation capability and the photosensitive component protection effect are reflected, and the optimal structure is ensured to have self stability and synergistic protection performance in a real compound system.

The application discloses a DNA binding small molecule high-throughput screening and characterization method, adopts a small molecule binding agent to program a toehold-mediated strand displacement (TMSD); performs one-stop comprehensive characterization of the interaction between the small molecule binding agent and double-stranded DNA, including dissociation constant, binding site size, thermodynamic parameters and sequence selectivity; performs high-throughput screening (HTS) identification of the small molecule binding agent by using a series of induced nucleic acid displacement BIND reaction system; and combines experimental measurement and computer simulation, and it is shown that the small molecule double-stranded DNA binding agent can be used in the reaction path of programming toehold-mediated strand displacement (TMSD), so that the molecular tool of comprehensive thermodynamic characterization can be performed by using the binding agent induced nucleic acid displacement (BIND) technology, and the high-throughput screening (HTS) of the small molecule double-stranded DNA binding agent can be performed without any special equipment, the application is widely used as a one-stop HTS and comprehensive characterization platform, so as to accelerate the pace of discovering novel small molecule double-stranded DNA binding drugs / tracers.

The present invention provides a composition that enables the achievement of a compound with which it is possible to produce a photoelectric conversion element that has small electric field intensity dependence of the response speed. A composition according to the present invention contains: a compound that is selected from the group consisting of a compound represented by formula (1) and a compound represented by formula (2); and an alcohol that has an acid dissociation constant pKa of 13.0 or less.

The invention discloses an anti-Cx43 Ser368 site phosphorylated specific monoclonal antibody as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The specific monoclonal antibody is prepared from a Cx43 Ser368 site phosphorylated antigen peptide immune animal, can be specifically combined with a Cx43 Ser368 phosphorylated form in PASMCs in a pulmonary arterial hypertension specimen, does not have a cross reaction with non-phosphorylated Cx43 or other site phosphorylated forms, has an equilibrium dissociation constant KD of less than or equal to 100 nM, can detect a phosphorylated signal induced by nicotine exposure in a dose-dependent manner, and can be used for preparing the specific monoclonal antibody. And PKC / Cx43-pS368 / MEK / ERK signal axis is used for associating the proliferation, migration, dedifferentiation and cardiopulmonary remodeling degree of the PASMC. The method has the beneficial effects of high specificity, high cell purity, excellent model pertinence, wide mechanism coverage, multiple application scenes, complete verification system and the like.

The invention discloses a nano antibody capable of specifically recognizing perfluorooctanoic acid and a preparation method of the nano antibody. The amino acid sequence of the VHH of the nano antibody is as shown in SEQ ID NO. 1. A VHH sequence capable of specifically recognizing perfluorooctanoic acid is screened from a phage display library by utilizing a synthesized perfluorooctanoic acid-BSA complete antigen, an expression engineering strain containing the VHH sequence is constructed, and the recombinant nano antibody is obtained after induced culture of the expression engineering strain. And the affinity and the specificity of the nano antibody and the perfluorooctanoic acid are verified. Results show that the sensitivity (IC50) of the nano antibody to perfluorooctanoic acid is 11.77 mu g / mL, the detection linear range is 9.132-99.83 mu g / mL, the lowest detection limit is 3.715 mu g / mL, the dissociation constant KD to perfluorooctanoic acid is 2.474 * 10 <-5 >, the cross reaction rate to other perfluorooctanoic acid structural analogues is smaller than or equal to 7.4%, and the nano antibody is good in sensitivity and specificity. The nano antibody provided by the invention has extremely high application value in detection of perfluorooctanoic acid or preparation of perfluorooctanoic acid detection products.

To provide anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using the antibodies and ADCs.SOLUTION: There is provided an anti-hEGFR antibody or an antigen binding portion thereof, a) that binds to an epitope within a specific amino acid sequence or competes, for binding to epidermal growth factor receptor variant III (EGFRvIII), with a second anti-hEGFR antibody comprising a heavy chain variable domain containing a specific amino acid sequence and a light chain variable domain containing a specific amino acid sequence; b) that binds to EGFR with a dissociation constant (Kd) of about 1×10-6M or less as determined by surface plasmon resonance; and c) that inhibits tumor growth in an in vivo human non-small-cell lung carcinoma xenograft assay with a tumor growth inhibition percentage (%) of at least about 50% relative to a human IgG antibody which is not specific for EGFR.SELECTED DRAWING: Figure 4

The invention relates to a nucleic acid aptamer for specifically recognizing fibroblast growth factor 10 (FGF10) protein as well as a screening method and application of the nucleic acid aptamer. The nucleic acid aptamer is at least one of FAS-1, FAS-4, FAS-9, FAS-10 and FAS-12, and is obtained by screening through a magnetic bead-SELEX (systematic evolution of ligands by exponential enrichment) technology. The aptamer can be combined with FGF10 protein with high affinity, the equilibrium dissociation constant (Kd) of the aptamer is within the range of 5-20 nM, and the aptamer has good recognition specificity. By means of the excellent performance, the nucleic acid aptamer has wide application prospects in construction of an efficient detection method of the FGF10 protein and research and development of an FGF10 antagonist.

The invention belongs to the technical field of analysis and testing, and particularly discloses a synchronous SERS detection method for three renal function markers in serum, which comprises the following steps: preparing Au (at) Ag (at) IP6 nanoparticles covered by IP6 by taking gold nanoparticles as seeds, and dripping the Au (at) Ag (at) IP6 nanoparticles on a gold-plated silicon chip to prepare a high-performance SERS chip; adding methanol into the serum to be detected to remove high-abundance large-protein impurities; different dissociation constants of the three markers are utilized, a buffer solution is added to regulate and control the pH value of serum to be alkaline, adsorption equilibrium of molecules of the three markers on the surface of an SERS chip is balanced, and mutual interference among SERS characteristic peaks of the markers is eliminated; carrying out a labeling experiment in serum according to the concentration range of the three markers in a human body, drawing a curve of SERS characteristic intensity changing along with the concentration, and carrying out synchronous analysis on the three markers; and carrying out SERS test on a clinical serum sample, and calculating the concentrations of the three markers in the clinical serum sample according to a curve that the SERS characteristic peak intensities of the three markers change along with the concentrations.

The invention discloses a nucleic acid aptamer OUC-Fx11-10T with high affinity to fucoxanthin, and belongs to the technical field of nucleic acid aptamers. The nucleotide sequence of the nucleic acid aptamer OUC-Fx11-10T with high affinity to fucoxanthine is as shown in SEQ ID NO. 18. The nucleic acid aptamer OUC-Fx11-10T has high affinity to fucoxanthine. The invention further discloses the application of the nucleic acid aptamer OUC-Fx11-10T in identification or detection of the fucoxanthin. According to the nucleic acid aptamer OUC-Fx11-10T with high affinity to the fucoxanthine, the affinity and dissociation constant of the nucleic acid aptamer OUC-Fx11-10T with the fucoxanthine is measured to be 86.1 nM through an isothermal titration thermal method, and the nucleic acid aptamer OUC-Fx11-10T has no obvious affinity to structural analogues of the fucoxanthine such as violaxanthin, neoxanthin, zeaxanthin and beta-carotene; the fucoxanthine aptamer has high affinity and good specificity to fucoxanthine, and can be used for identification or detection of fucoxanthine.

The application discloses a new medical use of procyanidin B2 as a carbonic anhydrase IV (CA4) inhibitor. The application first confirms, by surface plasmon resonance (SPR) technology, that procyanidin B2 has direct and specific in-vitro combination with CA4 protein, and the equilibrium dissociation constant KD value is 7.51 μM. The application further confirms, by molecular docking, that the binding energy is-8.4 kcal / mol, which is superior to traditional inhibitors such as acetazolamide. The application further confirms, by molecular dynamics simulation, that the complex has high stability. The application further confirms, by HK-2 cell experiments, that procyanidin B2 can directly down-regulate the background expression of CA4 protein and re-regulate the abnormally high expression of CA4 induced by Ang II. Animal reference examples prove that the acacia extract containing procyanidin B2 can effectively improve the pathological damage of the kidney of SHR rats, reduce collagen deposition, reduce inflammatory factors and restore the folate level by inhibiting CA4. The application provides a new candidate drug molecule for treating renal fibrosis, hypertensive nephropathy and other related diseases by targeting CA4, and has a wide clinical application prospect.

Provided is a method for suppressing false negative in immunochromatography or the like. A method for detecting a substance to be detected in a sample, which comprises treating the sample or an extract of the sample with a compound having a functional group having an acid dissociation constant (pKa) of 3 or less in water at 25 DEG C, or a salt thereof; and a method for suppressing false negative in immunochromatography or nucleic acid chromatography for detecting a substance to be detected in a sample, which comprises treating the sample or an extract of the sample with the compound or a salt thereof.